Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  alitretinoin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-14 of 14 for your search:
Start Over
Phase III Randomized, Double-Blind Study of 9-CRA Topical Gel vs Vehicle Gel for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 08/97)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1057T-31, NCI-V96-0867
Phase III Study of 9-cis-Retinoic Acid versus Tretinoin in Patients with Newly Diagnosed Acute Promyelocytic Leukemia (Summary Last Modified 04/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1057-77, NCI-V97-1291
Phase I/II Pilot Study of Topical 9-CRA for Cutaneous Kaposi's Sarcoma in HIV-Positive Patients (Summary Last Modified 04/95)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-94087A1, NCI-V94-0595
Phase I/II Pilot Study of Topical 9-CRA for Cutaneous T-Cell Lymphoma (Summary Last Modified 12/95)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDA-DM-94075, MSKCC-94098, NCI-V95-0620
Phase I/II Study of 9-CRA/IFN-A for Metastatic or Recurrent Renal Cell Carcinoma (Summary Last Modified 07/97)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: CAN-NCIC-IND88, NCI-V95-0754, IND88
Phase II Study of 9-CRA for Locally Advanced, Inoperable, or Recurrent Carcinoma of the Cervix (Summary Last Modified 04/96)
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: AECM-1199508304, NCI-T95-0063H, T95-0063
Phase II Study of Oral 9-cis-Retinoic Acid for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 10/97)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1057-28, NCI-V96-0974
Phase II Study of 9-cis-Retinoic Acid/Carboplatin in Carboplatin-Resistant Ovarian Cancer (Summary Last Modified 04/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1057-32, NCI-V96-1051
Phase II Study of Oral 9-cis-Retinoic Acid for Advanced Hormone-Refractory Prostate Cancer (Summary Last Modified 08/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L1057-33, NCI-V96-1052
Phase II Study of Oral 9-cis-Retinoic Acid for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 04/2001)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: AMC-002, NCI-T96-0042H
Phase I Study of 9-cis-Retinoic Acid in Pediatric Patients with Refractory Malignancies (Summary Last Modified 12/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: under 21
Sponsor: NCI
Protocol IDs: NCI-95-C-0030G, CCG-0948, NCI-T95-0037N, T95-0037
Phase I Study of 9-cis-Retinoic Acid plus Tamoxifen for Metastatic Carcinoma of the Breast (Summary Last Modified 10/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NYU-9440, NCI-T95-0080D, T95-0080
Phase I Study of 9-cis-Retinoic Acid and Tamoxifen in Advanced Breast Cancer (Summary Last Modified 03/2002)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-96-C-0080B, NCI-T95-0090N, T95-0090
Phase I Study of Oral 9-cis-Retinoic Acid plus Interferon alfa for AIDS-Related Kaposi's Sarcoma (Summary Last Modified 04/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NYU-9541, NCI-T96-0056H, T96-0056
Start Over